Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate Cancer
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Feb. 19, 2025 -- For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR) gene alterations, talazoparib (TALA) + enzalutamide (ENZA) is associated with improved overall survival versus placebo + ENZA, according to a study presented at the American Society of Clinical Oncology annual Genitourinary Cancers Symposium, held from Feb. 13 to 15 in San Francisco.
Neeraj Agarwal, M.D., from the Huntsman Cancer Institute at the University of Utah in Salt Lake City, and colleagues reported final overall survival (OS) data among patients with mCRPC unselected for HRR gene alterations who had improved radiographic progression-free survival with TALA + ENZA versus placebo + ENZA as first-line treatment in the phase 3 TALAPRO-2 trial.
A total of 805 patients were randomly assigned: 402 and 403 to TALA + ENZA and placebo + ENZA, respectively. At the data cutoff (Sept. 3, 2024), 52 and 60 percent of patients in the TALA + ENZA and placebo + ENZA arms, respectively, had died. The researchers found that the hazard ratio for OS was 0.796 (95 percent confidence interval, 0.661 to 0.958) for TALA + ENZA versus placebo + ENZA, with a median OS of 45.8 and 37.0 months, respectively. In patients who were HRR-deficient and in those who were HRR-nondeficient/unknown, OS favored TALA + ENZA versus placebo + ENZA (hazard ratios, 0.549 [95 percent confidence interval, 0.364 to 0.826] and 0.878 [95 percent confidence interval, 0.713 to 1.080], respectively). Updated radiographic progression-free survival data favored TALA + ENZA versus placebo + ENZA, consistent with the primary analysis (hazard ratio, 0.667; 95 percent confidence interval, 0.551 to 0.807).
"TALA + ENZA demonstrated a statistically significant and clinically meaningful improvement in OS versus standard-of-care ENZA," the authors write.
Several authors disclosed ties to Pfizer, which manufactures talazoparib.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
About One in Six Men With Grade Group 1 Prostate Cancer Has Intermediate-, High-Risk Disease
WEDNESDAY, Aug. 6, 2025 -- A proportion of men with grade group 1 (GG1) prostate cancer have a higher-risk disease than suggested by biopsy, according to a study published online...
Racial Differences Seen in Prostate Cancer Care Quality
WEDNESDAY, July 30, 2025 -- Black men with newly diagnosed prostate cancer have lower odds of overtreatment and confirmatory testing when compared with White men, according to a...
Risk for Death From Prostate Cancer Low With Guideline Care for Nonmetastatic Disease
MONDAY, July 14, 2025 -- Men with nonmetastatic prostate cancer receiving guideline-concordant care have a much higher risk for death from causes other than prostate cancer...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.